ArticleBMC endocrine disorders2026
Association between Body Fat composition and serum branched chain amino acids in patients with visceral obesity.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of BCAAs/BCKAs with pancreatic steatosis in patients with type 2 diabetes mellitus: A cross-sectional study.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity, especially visceral obesity, is a major health issue globally, leading to metabolic disorders. Visceral fat accumulation is closely linked to insulin resistance and metabolic abnormalities. The role of branched-chain amino acids (BCAAs, e.g. leucine, isoleucine, and valine) in metabolic health, particularly in visceral obesity, remains unclear. Further investigation is needed to elucidate the relationships among body fat composition, BCAAs, and metabolic dysfunction in visceral obesity. PURPOSE: This study investigates the correlation between serum BCAAs levels and body fat composition in individuals with visceral obesity, as well as the association between these levels and metabolic indicators.
methodsA total of 105 participants were recruited and categorized into three groups: obesity without type 2 diabetes mellitus (T2DM) (n = 52), obesity with T2DM (n = 32), and healthy controls (n = 21). All participants underwent assessments of anthropometric measurements, biochemical parameters, and serum amino acid profiles. Correlation tests and multiple linear regression models were used to analyze relationships among variables and potential associations.
resultsSerum BCAAs levels were significantly higher in both obese groups than in the healthy, normal-weight control group (p < 0.001). Compared with the healthy normal-weight controls, valine showed the greatest increase (obesity non-T2DM: 36.48 ± 8.33 µg/mL; obesity and T2DM: 43.46 ± 7.68 µg/mL; controls: 30.48 ± 4.19 µg/mL). In Pearson's analysis, BCAAs were positively associated with visceral fat area (VFA), body mass index (BMI), waist circumference (WC), body fat ratio, and IR-related markers (HOMA-IR, fasting insulin, and HbA1c) (all p < 0.05). Valine demonstrated the strongest correlations with HOMA-IR (r = 0.481, p < 0.001) and WC (r = 0.507, p < 0.001). Strong positive correlations were also observed between BCAAs and fasting glucose, fasting insulin, HbA1c, and lipid parameters. In multivariable models, valine was independently and positively associated with central adiposity, as reflected by WC (standardized β = 0.357, p = 0.001), and with insulin resistance, as assessed by HOMA-IR (standardized β = 0.306, p = 0.003). Leucine and isoleucine were independently associated with WC and fasting insulin levels, while no independent associations were observed for phenylalanine or tyrosine.
conclusionValine is associated with central adiposity and insulin resistance in obesity and was independently associated with WC and HOMA-IR. BCAAs profiling may help identify individuals with increased metabolic risk; however, further prospective studies are required to validate its clinical and predictive value.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.